Pilot Study of Executive Function Intervention to Improve Neurodevelopmental Outcomes in Adolescents With CHD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Congenital Heart Disease
- Sponsor
- Boston Children's Hospital
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Change from baseline scores at the computerized Working Memory Test from the NIH Toolbox Assessment of Neurological and Behavioral Function at post-treatment assessment (up to 2 weeks after cessation of the intervention).
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
Executive dysfunction can profoundly impact all dimensions of a child's development. Impairments in executive function are a central component of the neurodevelopmental phenotype associated with CHD, and manifest as behavioral dysregulation and problems with attention, working memory, and organization/planning abilities. Identifying effective treatment strategies is vital for providing optimal care for these patients. The Cogmed executive function intervention, an evidence-based computerized neurocognitive program, improves outcomes in several pediatric populations. The investigators propose to conduct a pilot study to evaluate its efficacy in reducing morbidities in patients with CHD. This is a single center, single blinded 2-arm randomized controlled trial to test the immediate post-treatment and 3-month follow-up efficacy of Cogmed intervention versus standard of care in adolescents with CHD.
Investigators
Jane W. Newburger
MD, Commonwealth Professor of Pediatrics
Boston Children's Hospital
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of CHD requiring open-heart surgery before age 1 year.
- •Ages 13-16 years old.
- •≥ 6 months post-cardiac surgery.
- •Followed-up at the Cardiology clinic of Boston Children's Hospital.
- •English and/or Spanish speaking.
- •Home internet access and a computer on which the Cogmed program can be installed
- •Informed consent of parent/guardian as well as assent of child.
Exclusion Criteria
- •Chromosomal anomalies and/or genetic syndromes.
- •Severe physical and/or sensory impairments (hearing, visual, or psychomotor).
- •IQ scores \<85 at baseline
- •Confirmed diagnosis of an autism spectrum disorder or a severe developmental disorder that would prevent successful completion of the planned study testing.
- •Scheduled to undergo major cardiac interventions in the 6 months following enrollment.
- •Received, receiving, or scheduled to receive Cogmed or any other computerized behavioral training program targeting executive functions or ADHD.
Outcomes
Primary Outcomes
Change from baseline scores at the computerized Working Memory Test from the NIH Toolbox Assessment of Neurological and Behavioral Function at post-treatment assessment (up to 2 weeks after cessation of the intervention).
Time Frame: Post-treatment assessment (up to 2 weeks after the cessation of the intervention)
This standardized measure assesses the ability to process information across a series of modalities (visual-spatial and verbal), to hold this information in a short-term buffer, and to actively manipulate it mentally. It is considered an excellent composite indicator of adolescents' executive function skills, as it requires the simultaneous implementation of control of attention and working memory abilities on tasks of increasing complexity. Mean scores are automatically computed and are compared to a standardization sample of US adolescents of the same age. They are normally distributed (mean=100, SD=15).